Tumour cells control communication between monocytes and B cells in inflammatory breast cancer

Inflammatory breast cancer (IBC) is a rare but aggressive breast cancer that is distinguished from non-IBC by its unique presentation, rapid progression and poor prognosis. Despite these clinical differences, genomic profiling has revealed very few driver mutations that are unique to IBC. Instead, IBC is characterised by enhanced activation of cellular pathways, including NF-kB and JAK/STAT signalling, and a distinct composition of the tumour immune microenvironment (TiME), including increased B cell and macrophage infiltration. How IBC tumour cells and immune cells interact to shape the unique TiME of IBC is largely unknown. We performed a comprehensive analysis of gene expression profiles from IBC and non-IBC patient samples, focusing on the abundance and co-occurrence of B cells with different immune cell subsets. To investigate how IBC cells modulate the TiME, we performed migration assays to determine the chemoattractive capacity of media conditioned by IBC cells (IBC-CM) for peripheral blood mononuclear cells (PBMCs) and B cells, both in the presence and absence of other immune subsets. Secretion of chemokines and cytokines by IBC cells was determined by immunoassays, and their contribution to mediating cell migration was examined using inhibitors and blocking antibodies. Survival analyses were performed to assess the association between immune cell infiltration patterns and patient prognosis. IBC tumours exhibited a higher abundance of B cells compared to non-IBC tumours, a finding that remained consistent across tumours with varying levels of tumour purity. We demonstrated that CXCL1 and CXCL8 produced by established IBC cell lines and primary IBC cells promote B cell migration. In addition, these chemokines also induce activation of the NF-kB and hypoxia pathways in monocytes, leading to increased secretion of IL-6, IL-10 and TNFα, which further amplify B cell recruitment. Analysis of clinical samples confirmed that this intercellular communication network defines a distinct cellular ecotype that is enriched in IBC. Importantly, co-infiltration of CD163+ monocytes/macrophages and CD79α+ B cells was more strongly associated with patient outcomes than either marker alone. IBC is characterised by enhanced inflammatory signalling programmes compared with non-IBC, driven by coordinated crosstalk among tumour cells, myeloid cells and B cells. This tripartite interaction shapes the immune architecture of the IBC TiME and influences patient survival. Therapeutic strategies targeting these interactions could provide novel IBC-specific treatment approaches.

Authors

Institutions

Publication Details

Journal
Breast Cancer Research
Published
2026-11-18
DOI
https://doi.org/10.1186/s13058-026-02386-6
Primary Topic
Immune cells in cancer
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Tumour cells control communication between monocytes and B cells in inflammatory breast cancer

Filipa C. Lynce, Peter A. van Dam, Fedor Berditchevski, Heather M. Long et al.
Breast Cancer Research
Immune cells in cancer
article

Tumour cells control communication between monocytes and B cells in inflammatory breast cancer

Filipa C. Lynce, Peter A. van Dam, Fedor Berditchevski, Heather M. Long, Christophe Van Berckelaer, John W.M. Martens, Steven Hayward, Steven Van Laere, Pascal Finetti, Naoto Tada Ueno, François Bertucci, Xiaoping Wang, Chloé Vermeulen, Carolina Schroder, Jing Zhang
article en

Abstract

Inflammatory breast cancer (IBC) is a rare but aggressive breast cancer that is distinguished from non-IBC by its unique presentation, rapid progression and poor prognosis. Despite these clinical differences, genomic profiling has revealed very few driver mutations that are unique to IBC. Instead, IBC is characterised by enhanced activation of cellular pathways, including NF-kB and JAK/STAT signalling, and a distinct composition of the tumour immune microenvironment (TiME), including increased B cell and macrophage infiltration. How IBC tumour cells and immune cells interact to shape the unique TiME of IBC is largely unknown. We performed a comprehensive analysis of gene expression profiles from IBC and non-IBC patient samples, focusing on the abundance and co-occurrence of B cells with different immune cell subsets. To investigate how IBC cells modulate the TiME, we performed migration assays to determine the chemoattractive capacity of media conditioned by IBC cells (IBC-CM) for peripheral blood mononuclear cells (PBMCs) and B cells, both in the presence and absence of other immune subsets. Secretion of chemokines and cytokines by IBC cells was determined by immunoassays, and their contribution to mediating cell migration was examined using inhibitors and blocking antibodies. Survival analyses were performed to assess the association between immune cell infiltration patterns and patient prognosis. IBC tumours exhibited a higher abundance of B cells compared to non-IBC tumours, a finding that remained consistent across tumours with varying levels of tumour purity. We demonstrated that CXCL1 and CXCL8 produced by established IBC cell lines and primary IBC cells promote B cell migration. In addition, these chemokines also induce activation of the NF-kB and hypoxia pathways in monocytes, leading to increased secretion of IL-6, IL-10 and TNFα, which further amplify B cell recruitment. Analysis of clinical samples confirmed that this intercellular communication network defines a distinct cellular ecotype that is enriched in IBC. Importantly, co-infiltration of CD163+ monocytes/macrophages and CD79α+ B cells was more strongly associated with patient outcomes than either marker alone. IBC is characterised by enhanced inflammatory signalling programmes compared with non-IBC, driven by coordinated crosstalk among tumour cells, myeloid cells and B cells. This tripartite interaction shapes the immune architecture of the IBC TiME and influences patient survival. Therapeutic strategies targeting these interactions could provide novel IBC-specific treatment approaches.

Breast Cancer Research
Centre National de la Recherche Scientifique (FR), Harvard University (US), University of Antwerp (BE), Inserm (FR), Breast Cancer Research Foundation (US), Aix-Marseille Université (FR), Erasmus MC (NL), The Netherlands Cancer Institute (NL), Cancer Center of Hawaii (US), Antwerp University Hospital (BE), Dana-Farber Cancer Institute (US), Cancer Clinic (US), AZ Turnhout (BE), Cancer Research UK Clinical Trials Unit (GB), Centre de Recherche en Cancérologie de Marseille (FR), Erasmus MC Cancer Institute (NL), Institut Paoli-Calmettes (FR), University of Hawaii Cancer Center (US), University of Birmingham (GB)
Breast Cancer Now, Fonds Wetenschappelijk Onderzoek, Ligue Contre le Cancer, KWF Kankerbestrijding
Good health and well-being
Immune cells in cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon